INFUSYSTEM HOLDINGS INC (INFU)
Health Care · Medical Equipment & Services · NYSE American
A national healthcare service provider facilitating clinic-to-home infusion therapy through durable medical equipment rental, sales, and comprehensive patient support services.
What INFUSYSTEM HOLDINGS INC does
InfuSystem Holdings is a national healthcare service provider that facilitates outpatient care by providing durable medical equipment (DME), primarily infusion pumps, and related services to oncology practices, hospitals, and surgery centers. The company operates through two segments: Patient Services, which provides turnkey clinic-to-home solutions including equipment, logistics, and billing, and Device Solutions, which offers medical equipment rentals, sales, and biomedical support services.
Recent developments
The company reported strong Q2 2026 financial results with 2.6% revenue growth and successfully expanded its oncology and wound care segments. Management reaffirmed its full-year 2026 guidance, targeting 6-8% pro forma revenue growth while continuing to optimize its new ERP system and share repurchase program.
From INFUSYSTEM HOLDINGS INC's filing of 2026-08-04.
Themes: oncology / cancer care, clinic-to-home healthcare, wound care / lymphedema therapy, durable medical equipment (DME), biomedical services
Fundamentals
- Price$14.23 as of 2026-10-20 close
- Market cap$283M as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return+48.2% 2025-10-20 close $9.60 → 2026-10-20 close $14.23
- P/E35.57 as of 2026-10-20
- Net margin+4.6% FY2025, SEC XBRL
- Gross margin+56.0% FY2025, SEC XBRL
- ROE+11.6% FY2025, SEC XBRL
- ROIC+9.6% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31)
- Debt / equity0.35 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+6.4% FY2025, SEC XBRL
- Revenue CAGR (3y)+9.3% SEC XBRL
- Beta1.13 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How INFU compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $37M | $21M | $4M | $3M | $0.15 | $7M† | $91000† |
| Q1 FY2026 2026-03-31 | $34M | $20M | $2M | $1M | $0.05 | $970000 | $157000 |
| Q4 FY2025 2025-12-31 | $36M† | $20M† | $4M† | $2M† | $0.09† | $7M† | $133000† |
| Q3 FY2025 2025-09-30 | $36M | $21M | $4M | $2M | $0.11 | $8M† | $79000† |
| Q2 FY2025 2025-06-30 | $36M | $20M | $4M | $3M | $0.12 | $7M† | $217000† |
| Q1 FY2025 2025-03-31 | $35M | $19M | $618000 | -$267000 | -$0.01 | $2M | $131000 |
| Q4 FY2024 2024-12-31 | $34M† | $18M† | $3M† | $933000† | $0.04† | $8M† | $530000† |
| Q3 FY2024 2024-09-30 | $35M | $19M | $3M | $2M | $0.08 | $10M† | $43000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$964000
- Total debt$20M borrowings only; leases excluded
- Net debt$19M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How INFUSYSTEM HOLDINGS INC looks technically
INFUSYSTEM HOLDINGS INC (INFU) is trading 40.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 59 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high).
Trend
8
| Distance from the 200-day | it is trading 40.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +40.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.68 | $12.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.11 | $10.11 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 12.47. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 59 trading days ago — a "golden cross", a bullish long-term signal | 59 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control | 38.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30) | 68.9 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($12.62 to $14.28) — its "stochastic" reading is 97 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 97.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.28 | $14.28 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.3% |
| Above the 52-week low | it is 95.2% above its 52-week low (its lowest price of the past year) | +95.2% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.3% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $23.26 (set on 2021-03-17) | $23.26 |
| Given back of the 52-week move | over the past year its closes ranged ($7.42 to $14.23), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.80 to $10.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 38.8% below its all-time high | -38.8% |
| Nearest price level | it is trading 17.1% above a support level at $11.79 — a price it turned at twice since 2026-08-26, most recently on 2026-09-14. Since 2024-10-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -17.1% |
| All-time low | its lowest closing price on record is $0.75 (set on 2011-09-26) | $0.75 |
| Above the all-time low | it is 1797.3% above its all-time low | +1,797% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4365 between its high and its low — about 3.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4365 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.45 and $14.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.45 – $13.30 – $14.14 |
| Typical daily range (% of price) | its price moves about 3.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.1% |
| Stretch from the 200-day average | it is trading 9.4 daily ranges above its 200-day average price (40.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.88× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Open gap | it gapped 10.0% above the previous close 54 sessions ago and has not traded back through the level it left behind at 9.22 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +10.0% |
|---|---|---|
| Gap filled | a 2.0% gap down opened on 2026-08-05 has been "filled" 53 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 53 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.19% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.8 percentage points (the stock gained 10.7% while the market gained 1.0%) | +9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 55.5 percentage points (the stock gained 59.2% while the market gained 3.6%) | +55.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 23.4 percentage points (the stock gained 31.9% while the market gained 8.5%) | +23.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 33.7 percentage points (the stock gained 48.2% while the market gained 14.6%) | +33.7% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +17.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 42% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.03 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | +41.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $12.60 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +12.9% |
Price levels it has turned at before
INFU last closed at $14.23 on 2026-10-20. Since 2024-10-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.79 | Support | 17.1% below the last close | turned there twice · 2026-08-26 to 2026-09-14 |
| $10.97 | Support | 22.9% below the last close | turned there four times · 2025-08-29 to 2026-04-27 |
| $10.67 | Support | 25.0% below the last close | turned there three times · 2025-09-23 to 2026-05-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $12.47.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $12.82 and $13.37 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 16 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$16.83 range $15.00 – $18.00; median $17.50
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INFU
- Consensus EPS estimate$0.12 next reporting period, as of 2026-10-16
- Estimate change, 30 days$0.00 (0.0%) from $0.12, on 2026-09-11, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["dependence on third-party healthcare reimbursement and insurance coverage","exposure to changes in government healthcare policies and CMS fee schedules","concentration risk related to key contracts and customers"]
What changed in the latest 10-Q
AI-assisted comparison of INFU's 10-Q filed 2026-08-04 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Reworded:
- In the newer filing (filed 2026-08-04), the page number shown after 'cybersecurity risks' is 23; in the older filing (filed 2026-05-08), the page number shown is 20.
- Notes:
- Both provided texts appear to be truncated at 'A cancer patient can' and may not include the full MD&A section.
- Aside from the page number difference, the compared portions of the two texts are identical.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-164 buys ($131469) · 0 sells — 3 buying insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of INFU within a 30-day window between 2026-05-08 and 2026-05-11. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-11. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INFU's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding INFU as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,731,263
- Reported value $26,356,690
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about INFU's institutional holders → See what each manager we track holds →
Short interest (FINRA)
INFU had 864,075 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
INFU had 4.34% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.22 days to cover at the same settlement.
- Reported short interest (shares) 864,075
- Short interest (% of shares outstanding) 4.34%
- Prior settlement (shares) 812,365
- Reported change 6.37%
- Days to cover (reported) 5.22
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Baxter International (BAX)
- Becton Dickinson (BDX)
- ICU Medical (ICUI)
- Fresenius Medical Care (FMS)
- Zoll Medical Corporation (Asahi Kasei)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INFU vs…
Frequently asked questions
What does INFUSYSTEM HOLDINGS INC (INFU) do?
InfuSystem Holdings is a national healthcare service provider that facilitates outpatient care by providing durable medical equipment (DME), primarily infusion pumps, and related services to oncology practices, hospitals, and surgery centers. The company operates through two segments: Patient Services, which provides turnkey clinic-to-home solutions including equipment, logistics, and billing, and Device Solutions, which offers medical equipment rentals, sales, and biomedical support services.
What sector is INFUSYSTEM HOLDINGS INC (INFU) in?
INFUSYSTEM HOLDINGS INC (INFU) is classified in the Health Care sector. Its industry is Medical Equipment & Services. It trades on NYSE American.
Who are INFUSYSTEM HOLDINGS INC's (INFU) competitors?
Notable peers of INFUSYSTEM HOLDINGS INC (INFU) include Baxter International, Becton Dickinson, ICU Medical, Fresenius Medical Care and Zoll Medical Corporation (Asahi Kasei). This peer set is informational only — not financial advice.
Is INFUSYSTEM HOLDINGS INC (INFU) overbought or oversold right now?
INFUSYSTEM HOLDINGS INC (INFU) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 69, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INFU come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.